4//SEC Filing
Crockett Thomas Andrew 4
Accession 0001415889-24-004710
CIK 0001348911other
Filed
Feb 20, 7:00 PM ET
Accepted
Feb 21, 9:41 PM ET
Size
17.7 KB
Accession
0001415889-24-004710
Insider Transaction Report
Form 4
Crockett Thomas Andrew
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2024-02-20$14.11/sh−24,888$351,289→ 211,203 total - Exercise/Conversion
Performance Stock Units
2024-02-17−20,833→ 62,500 total→ Common Stock (20,833 underlying) - Exercise/Conversion
Common Stock
2024-02-17+54,415→ 236,091 total - Exercise/Conversion
Performance Stock Units
2024-02-17−20,833→ 20,834 total→ Common Stock (20,833 underlying) - Exercise/Conversion
Restricted Stock Unit
2024-02-17−5,805→ 52,245 total→ Common Stock (5,805 underlying) - Exercise/Conversion
Restricted Stock Unit
2024-02-17−6,944→ 48,612 total→ Common Stock (6,944 underlying)
Footnotes (7)
- [F1]Each restricted stock unit ("RSU") and performance stock unit ("PSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs and PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.75 to $14.1289 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on August 17, 2022, subject to continued service through each vesting date.
- [F5]1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 17, 2022, subject to continued service through each vesting date.
- [F6]Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on June 8, 2023. Each PSU represents a contingent right to receive one share of Issuer Common Stock upon the Issuer's achievement of performance metric goals ("Performance Metrics"). 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of August 17, 2023, upon Performance Metrics achieved, subject to continued service through each vesting date.
- [F7]Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on January 10, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Metrics. 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of February 17, 2024, upon Performance Metrics achieved, subject to continued service through each vesting date.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeother
Related Parties
1- filerCIK 0001690920
Filing Metadata
- Form type
- 4
- Filed
- Feb 20, 7:00 PM ET
- Accepted
- Feb 21, 9:41 PM ET
- Size
- 17.7 KB